Viatris rises as FDA begins review of eye drop for age‑related near‑vision loss

Viatris

25/02/2026 12:24

** Shares of generic drugmaker Viatris VTRS.O rise 1.5% to $16.31 premarket

** Co says FDA accepted its application to expand Ryzumvi’s use for the treatment of presbyopia, an age‑related condition that makes it harder to see things up close

** Presbyopia affects most people over 45; causes blurred near vision and eye strain

** Co says filing is backed by two late‑stage studies showing improved near vision with no serious side effects

** FDA decision expected by October 17, 2026, per co

** Shares down ~27% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))